Latest news

• NICE U-turn on Opdivo for kidney cancer

  happy that NICE has made this recommendation for patients with advanced kidney cancer and their families.”. ... Nick Turkentine, chief executive of Kidney Cancer UK, said: “Today's landmark decision is hugely welcome news for kidney cancer patients

• Italian pharma scandals prompts call for EU-wide pricing probe

  Aspen fined 5.2m for threat to halt supply of cancer drugs if price hikes not accepted. ... a possible link between drug shortages and inflated pricing.

• NICE turns down Keytruda for lung cancer in draft guidance

  Says long-term benefits for advanced non-small cell lung cancer treatment not proven. ... NICE has been taking an increasingly tough stance on cancer drug pricing, holding out for steep discounts in order to reduce the NHS' spending on medicines.

• NICE backs five new drugs after discounts agreed

  The UK drug-prescribing watchdog has backed the funding of five new drugs for cancer, high cholesterol and a chronic and debilitating skin disease. ... NICE had previously recommended the use of Tafinlar in melanoma in 2014 - before GlaxoSmithKline (GSK)

• Tension expected as cancer market rises to $150bn-plus

  Last year, cancer drug sales were $107bn, an 11.5% increase on the $90bn recorded in the prior year, says the report, which has been published just as the American Society ... Debate on cancer drug pricing is expected to feature prominently alongside